SG11201803218PA - Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection - Google Patents
Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protectionInfo
- Publication number
- SG11201803218PA SG11201803218PA SG11201803218PA SG11201803218PA SG11201803218PA SG 11201803218P A SG11201803218P A SG 11201803218PA SG 11201803218P A SG11201803218P A SG 11201803218PA SG 11201803218P A SG11201803218P A SG 11201803218PA SG 11201803218P A SG11201803218P A SG 11201803218PA
- Authority
- SG
- Singapore
- Prior art keywords
- progression
- methods
- gene therapy
- neurodegenerative diseases
- disease onset
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245824P | 2015-10-23 | 2015-10-23 | |
PCT/US2016/058484 WO2017070678A1 (en) | 2015-10-23 | 2016-10-24 | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803218PA true SG11201803218PA (en) | 2018-05-30 |
Family
ID=58558125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803218PA SG11201803218PA (en) | 2015-10-23 | 2016-10-24 | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
Country Status (10)
Country | Link |
---|---|
US (1) | US20180236105A1 (de) |
EP (1) | EP3364970B1 (de) |
JP (2) | JP7190352B2 (de) |
KR (1) | KR20180067684A (de) |
CN (2) | CN116650668A (de) |
AU (1) | AU2016341428B2 (de) |
BR (1) | BR112018008069A2 (de) |
CA (1) | CA3002654A1 (de) |
SG (1) | SG11201803218PA (de) |
WO (1) | WO2017070678A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3747998A1 (de) | 2013-03-15 | 2020-12-09 | The Trustees of the University of Pennsylvania | Zusammensetzungen zur behandlung von mpsi |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
BR112017009497A2 (pt) | 2014-11-05 | 2018-02-06 | Voyager Therapeutics, Inc. | polinucleotídeos de aadc para o tratamento da doença de parkinson |
KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
BR112017010087A2 (pt) | 2014-11-14 | 2018-06-05 | Voyager Therapeutics, Inc. | composições e métodos para tratar esclerose lateral amiotrófica (ela) |
EP3230441A4 (de) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur herstellung von scaav |
SG11201806270XA (en) | 2016-02-03 | 2018-08-30 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
EP3448987A4 (de) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
MX2018014154A (es) | 2016-05-18 | 2019-05-06 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
EP3831281A1 (de) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon |
EP3534892A4 (de) * | 2016-11-04 | 2020-05-27 | The Children's Hospital of Philadelphia | Gentransferzusammensetzungen, verfahren und verwendungen zur behandlung von neurodegenerativen erkrankungen |
EP3619308A4 (de) | 2017-05-05 | 2021-01-27 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von morbus huntington |
AU2018261790A1 (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
KR20200023280A (ko) * | 2017-05-11 | 2020-03-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신경 세로이드 지질갈색소증에 대한 유전자 요법 |
BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
BR112020000063A2 (pt) | 2017-07-06 | 2020-07-14 | The Trustees Of The University Of Pennsylvania | terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
EP4124658A3 (de) | 2017-10-16 | 2023-04-19 | Voyager Therapeutics, Inc. | Behandlung von amyotropher lateralsklerose (als) |
MX2021009250A (es) * | 2019-02-01 | 2021-11-04 | Spark Therapeutics Inc | Metodos de tratamiento por vectores aav para la lipofuscinosis ceroidea neuronal infantil tardia tipo 2. |
AU2020271052A1 (en) * | 2019-04-08 | 2021-10-28 | The Children's Hospital Of Philadelphia | Treatment of lysosomal storage disease in the eye through administration of AAVs expressing TPP1 |
CN114828960A (zh) * | 2019-08-29 | 2022-07-29 | 生物马林药物股份有限公司 | 治疗儿童个体的cln2病的方法 |
WO2021180118A1 (en) * | 2020-03-11 | 2021-09-16 | Shanghai Belief-Delivery Biomed Co., Ltd. | Novel use of aspirin compound in increasing nucleic acid expression |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2745470T3 (es) * | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
CN115120745A (zh) * | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
KR20220106852A (ko) * | 2013-07-26 | 2022-07-29 | 유니버시티 오브 아이오와 리써치 파운데이션 | 뇌 질환을 치료하기 위한 방법 및 조성물 |
-
2016
- 2016-10-24 CN CN202310053553.2A patent/CN116650668A/zh active Pending
- 2016-10-24 BR BR112018008069A patent/BR112018008069A2/pt active Search and Examination
- 2016-10-24 KR KR1020187014536A patent/KR20180067684A/ko not_active Application Discontinuation
- 2016-10-24 JP JP2018520439A patent/JP7190352B2/ja active Active
- 2016-10-24 SG SG11201803218PA patent/SG11201803218PA/en unknown
- 2016-10-24 CA CA3002654A patent/CA3002654A1/en active Pending
- 2016-10-24 EP EP16858441.5A patent/EP3364970B1/de active Active
- 2016-10-24 US US15/769,931 patent/US20180236105A1/en active Pending
- 2016-10-24 AU AU2016341428A patent/AU2016341428B2/en active Active
- 2016-10-24 CN CN201680075712.7A patent/CN108601771B/zh active Active
- 2016-10-24 WO PCT/US2016/058484 patent/WO2017070678A1/en active Application Filing
-
2022
- 2022-06-27 JP JP2022102692A patent/JP2022123145A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3364970B1 (de) | 2024-02-07 |
CA3002654A1 (en) | 2017-04-27 |
CN108601771B (zh) | 2023-02-21 |
JP7190352B2 (ja) | 2022-12-15 |
CN108601771A (zh) | 2018-09-28 |
BR112018008069A2 (pt) | 2018-11-13 |
EP3364970A4 (de) | 2019-04-24 |
KR20180067684A (ko) | 2018-06-20 |
US20180236105A1 (en) | 2018-08-23 |
JP2022123145A (ja) | 2022-08-23 |
WO2017070678A1 (en) | 2017-04-27 |
AU2016341428B2 (en) | 2021-12-02 |
EP3364970A1 (de) | 2018-08-29 |
CN116650668A (zh) | 2023-08-29 |
AU2016341428A1 (en) | 2018-05-17 |
JP2018535955A (ja) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201803218PA (en) | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection | |
HK1246712A1 (zh) | 神經刺激治療疾病及病症 | |
HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
IL263641A (en) | Pharmaceutical preparations and their use for the treatment of cancer and autoimmune diseases | |
EP3389725A4 (de) | Zusammensetzungen und verfahren zur behandlung von erkrankungen des zentralen nervensystems | |
SG11201707832RA (en) | Rna containing composition for treatment of tumor diseases | |
IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
IL290980A (en) | Rna for the treatment of autoimmune diseases | |
ZA201702214B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
ZA201903003B (en) | Treatment of neurological diseases | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
HK1253299A1 (zh) | 一種通過基因治療治療眼疾病的改進方法 | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
EP3341012A4 (de) | Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden | |
HK1245671A1 (zh) | 使用白細胞介素-10治療疾病和病症的方法 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
GB201604253D0 (en) | Treatment of genetic diseases | |
GB201517565D0 (en) | Treatment of genetic diseases |